Veracyte Has Released Our Inaugural ESG Report Read More
Search Open Mobile Menu
Veracyte Has Released Our Inaugural ESG Report Read More

Veracyte® Investor Relations

Veracyte is a global diagnostics company that improves patient care by providing answers to clinical questions, informing diagnosis and treatment decisions throughout the patient journey in cancer and other diseases. The company’s growing menu of diagnostic tests leverages advances in genomic science and technology, enabling patients to avoid risky, costly diagnostic procedures and quicken time to appropriate treatment.
The company’s tests in lung cancer, prostate cancer, breast cancer, thyroid cancer, bladder cancer, and idiopathic pulmonary fibrosis are available to patients and its renal cancer and lymphoma subtyping tests are in development, the latter as a companion diagnostic. With Veracyte’s exclusive global license to a best-in-class diagnostics instrument platform, the company is positioned to deliver its genomic tests to patients worldwide. Veracyte is based in South San Francisco, California.

Press Releases

Date Title and Summary Additional Formats
Toggle Summary New Data To Be Shared at 2023 ASCO Demonstrate Power of Veracyte’s Decipher GRID To Help Advance Molecular Understanding of Prostate Cancer
SOUTH SAN FRANCISCO, Calif. --(BUSINESS WIRE)--May 25, 2023-- Veracyte, Inc . (Nasdaq: VCYT) announced that new data to be shared at the 2023 American Society of Clinical Oncology (ASCO) Annual Meeting demonstrate the ability of the company’s Decipher Genomics Resource for Intelligent Discovery
Toggle Summary New Data Presented at ATS 2023 Reinforce Clinical Utility of Veracyte’s Genomic Tests in Interstitial Lung Disease and Lung Cancer
SOUTH SAN FRANCISCO, Calif. --(BUSINESS WIRE)--May 24, 2023-- Veracyte, Inc. (Nasdaq: VCYT) today announced new data suggesting its novel genomic tests may positively impact diagnosis and care for patients being evaluated for interstitial lung disease (ILD) or lung cancer.


Date Event Details
Summary Toggle Jun 6, 2023 9:40 AM EDT
William Blair 43rd Annual Growth Stock Conference
Summary Toggle Jun 13, 2023 6:20 PM EDT
Goldman Sachs 44th Annual Global Healthcare Conference


Title Documents

Corporate Presentation May 2023